Aroa Biosurgery Limited (ARX.AX)

0,5400 -0,0050 (-0,92%) Alla chiusura: 04:10PM AEST

Aroa Biosurgery Limited

64 Richard Pearse Drive
Airport Oaks Mangere
Auckland 2022
New Zealand
64 9 869 3035
https://aroabio.com

Settore/i: Healthcare
Settore: Medical Devices
Impiegati a tempo pieno: 

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Brian Ward	Founder, CEO, MD & Executive Director	666,92k	N/D	N/D
Mr. James Agnew BCom, LLB	CFO & Joint Company Secretary	347,13k	N/D	N/D
Mr. Scott Sherriff B.A., M.B.A.	Chief Operating Officer	N/D	N/D	N/D
Dr. Barnaby C.H. May Ph.D.	Chief Scientific Officer	N/D	N/D	N/D
Ms. Neetha Alex-Kumar	General Counsel	N/D	N/D	N/D
Mr. Frazer Murray	Director of Global Marketing & Strategy	N/D	N/D	N/D
Ms. Yasmin Winchester B.Sc.	Vice President of Quality, Regulatory & Sustainability	N/D	N/D	N/D
Ms. Tracy Weimar BA, MBA	Joint Company Secretary	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in AUD.

Descrizione

Aroa Biosurgery Limited, a regenerative medicine company, engages in the developing, manufacturing, and sells medical devices for wound and tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobia Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; Myriad Morcells, a morcellized (powdered) format of Myriad Matrix for soft tissue repair and complex wounds; and Reinforced Bioscaffolds, a surgical product for use in ventral hernia repair and abdominal wall reconstruction. The company was incorporated in 2007 and is headquartered in Auckland, New Zealand.

Governance aziendale

L'ISS Governance QualityScore di Aroa Biosurgery Limited al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.